Stock slumps for Tel Aviv's Galmed fol­low­ing PhI­Ia NAFLD flop

The stock price is cra­ter­ing for thin­ly-trad­ed Tel Aviv com­pa­ny Galmed Phar­ma­ceu­ti­cals $GLMD, which just an­nounced a Phase IIa let­down of its non-al­co­holic fat­ty liv­er dis­ease pro­gram.

The mid-stage study was eval­u­at­ing Aram­chol in 50 pa­tients with HIV-as­so­ci­at­ed lipody­s­tro­phy and non-al­co­holic fat­ty liv­er dis­ease. The study, called Ar­rive, failed to meet the pri­ma­ry end­point of an im­prove­ment in liv­er fat at week 12.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.